Riskpilot← Back to searchSign inGet full accessEIR SCIENCES ApS
APSActiveCVR 35380485Kongevejen 381Wholesale of information and communication equipment · NACE 4650Est. 20132 employeeseirsicences.com
Revenue 2024
DKK 4,3M
+15% vs 2023
EBITDA margin
18.0%
+394% vs 2023
Equity ratio
21.5%
Financial strength
Net profit 2024
DKK 569K
+365% vs 2023
| Revenue | DKK 4,3M | +15% |
| EBITDA | DKK 776K | +394% |
| Net profit | DKK 569K | +365% |
| Total assets | DKK 4,6M | +137% |
| Equity | DKK 997K | +133% |
| Employees | 2 | — |
Legal name
EIR SCIENCES ApS
CVR number
35380485
Legal form
Anpartsselskab
NACE code
4650 · Wholesale of information and communication equipment
Founded
12. juni 2013
Share capital
DKK 80.000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør
Company purpose
Selskabets formål er at drive teknologisk service på kommercielt grundlag indenfor det bio-medicinske, bioteknologiske og biomedikotekniske område ved udbud på markedsmæssige vilkår af kontraktforskning, forskningsbaseret service, licensgivning og rådgivning baseret på selskabets forsknings- og udviklingsplatforme samt andre aktiviteter, der efter bestyrelsens skøn er i forbindelse hermed
Address
Kongevejen 381
Phone
+4528948133
Email
mnielsen@eirsciences.com
Website
eirsicences.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -95 | 391 | 188 | 466 | 813 | 279 | 685 | 966 | 2.131 | 1.951 | 3.763 | 4.314 |
| Staff expenses | -2 | -265 | -52 | -351 | -315 | -87 | -399 | -826 | -1.816 | -1.809 | -3.606 | -3.538 |
| EBITDA | -97 | 126 | 54 | 60 | 105 | 3 | 155 | 140 | 315 | 141 | 157 | 776 |
| Depreciation & amort. | -5 | -5 | -5 | -5 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -102 | 121 | 49 | 55 | 105 | 3 | 155 | 140 | 315 | 141 | 157 | 776 |
| Net financials | -2 | -0 | -1 | -0 | 0 | 0 | -7 | -9 | -8 | -14 | -22 | -24 |
| Profit before tax | -104 | 121 | 47 | 55 | 105 | 3 | 148 | 131 | 307 | 127 | 136 | 752 |
| Tax | -15 | 19 | 6 | 12 | 23 | 1 | 55 | 30 | 66 | 28 | 13 | 183 |
| Net profit | -90 | 102 | 41 | 43 | 82 | 2 | 93 | 101 | 240 | 99 | 122 | 569 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 198 | 475 | 246 | 377 | 362 | 157 | 436 | 1.244 | 1.032 | 1.437 | 1.949 | 4.629 |
| Equity | 66 | 80 | 85 | 80 | 80 | 82 | 175 | 221 | 361 | 306 | 428 | 997 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 132 | 395 | 161 | 297 | 282 | 75 | 260 | 1.023 | 670 | 1.132 | 1.521 | 3.632 |
| Total debt | 132 | 395 | 161 | 297 | 282 | 75 | 260 | 1.023 | 670 | 1.132 | 1.521 | 3.632 |
EBITDA margin
18.0%
This company
15.8%
Market median
+14% vs market
20132024
Equity ratio
21.5%
This company
38.2%
Market median
-44% vs market
20132024
Return on equity
57.1%
This company
18.4%
Market median
+210% vs market
20132024
Net profit margin
13.2%
This company
8.1%
Market median
+63% vs market
20132024
Asset turnover
0.93×
This company
1.12×
Market median
+17% vs market
20132024
Debt / equity
3.64×
This company
0.62×
Market median
-487% vs market
20132024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
CL Founder | Founder | 2013 | — | — |
MN Management | Management | 2016 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2025 | — | — | |
| Board of Directors | 2013 | — | — | |
| Chairman | 2013 | — | — | |
OL | Board of Directors | 2013 | — | — |
| Board of Directors | 2013 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
EIR HOLDING ApS | Company | 100.0% | 100.0% | 2013 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
EIR HOLDING ApS
EIR SCIENCES ApS Board members of EIR SCIENCES ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Claus Lundegaard | Founder | 0 companies |
| Morten Nielsen | Management | 0 companies |
| Jens Vindahl Kringelum | Chairman | 0 companies |
| Tine Gold | Board of Directors | 0 companies |
| Anders Ekelund Mørck | Chairman | 0 companies |
| Ole Lund | Board of Directors | 0 companies |
| Julie Serritslev | Board of Directors | 0 companies |